

ASX ANNOUNCEMENT

RECORD \$2M SALES FOR CELLMID'S FGF5 INHIBITORS

SYDNEY, Wednesday, 10 January 2018: Cellmid Limited (ASX: CDY) (the **Company**), is pleased to advise that sales of its FGF5 inhibitor hair growth and anti-aging hair care products for the second quarter of FY2018 reached **\$2,025,451***, an increase of 115% from the same period last year. (2QFY2017: \$943K).

This is the first time the Company has recorded sales above \$2 million for the quarter, and it is a 34% increase on the highest previous quarterly result of \$1.5 million, which was achieved during the third quarter of FY2017, and coincided with the second QVC 'million dollar day' event.

The substantial increase in quarterly sales was the result of continued success with television shopping channel QVC, as well as the commencement of shipping to China following the receipt of import permits for the Jo-Ju® and Lexilis® branded products.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalsz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lyramid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, Japan, USA and China and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

*The sales figure was calculated using current exchange rates between the Australian Dollar and the Japanese Yen and US Dollar.

For personal use only